-$0.39 Earnings Per Share Expected for Tandem Diabetes Care Inc (TNDM) This Quarter

Equities analysts expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to post ($0.39) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Tandem Diabetes Care’s earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.36). Tandem Diabetes Care posted earnings of ($3.09) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 87.4%. The business is expected to announce its next quarterly earnings results on Thursday, October 25th.

According to Zacks, analysts expect that Tandem Diabetes Care will report full-year earnings of ($3.17) per share for the current year, with EPS estimates ranging from ($3.59) to ($2.81). For the next year, analysts expect that the firm will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.25) to ($0.54). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Monday, July 30th. The medical device company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.82). The business had revenue of $34.10 million for the quarter, compared to the consensus estimate of $29.68 million. Tandem Diabetes Care’s revenue for the quarter was up 60.1% compared to the same quarter last year. During the same period last year, the business posted ($0.44) earnings per share.

TNDM has been the subject of several research reports. Stifel Nicolaus reissued a “hold” rating and issued a $25.00 price objective (up from $7.50) on shares of Tandem Diabetes Care in a research report on Tuesday, July 31st. Lake Street Capital boosted their price objective on shares of Tandem Diabetes Care to $35.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. ValuEngine cut shares of Tandem Diabetes Care from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 2nd. BidaskClub cut shares of Tandem Diabetes Care from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Finally, Oppenheimer set a $15.00 price objective on shares of Tandem Diabetes Care and gave the company a “buy” rating in a research report on Sunday, May 27th. Three investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $30.85.

Tandem Diabetes Care stock traded up $2.43 during trading hours on Wednesday, hitting $40.80. The company had a trading volume of 316,235 shares, compared to its average volume of 3,216,886. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of -3.04 and a beta of 0.02. The company has a debt-to-equity ratio of 2.97, a current ratio of 3.02 and a quick ratio of 2.43. Tandem Diabetes Care has a 1 year low of $2.14 and a 1 year high of $40.04.

In other Tandem Diabetes Care news, Director Richard P. Valencia purchased 1,754 shares of Tandem Diabetes Care stock in a transaction dated Friday, August 3rd. The stock was acquired at an average price of $28.50 per share, for a total transaction of $49,989.00. Following the acquisition, the director now owns 1,754 shares in the company, valued at approximately $49,989. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 9.30% of the company’s stock.

Large investors have recently bought and sold shares of the company. Gabelli Funds LLC bought a new stake in shares of Tandem Diabetes Care in the 1st quarter valued at about $102,000. Cetera Advisor Networks LLC bought a new position in shares of Tandem Diabetes Care during the 1st quarter worth approximately $117,000. Legal & General Group Plc bought a new position in shares of Tandem Diabetes Care during the 2nd quarter worth approximately $147,000. Element Capital Management LLC bought a new position in shares of Tandem Diabetes Care during the 1st quarter worth approximately $184,000. Finally, A.R.T. Advisors LLC raised its stake in shares of Tandem Diabetes Care by 284.4% during the 1st quarter. A.R.T. Advisors LLC now owns 38,518 shares of the medical device company’s stock worth $191,000 after acquiring an additional 28,499 shares in the last quarter. Institutional investors and hedge funds own 62.77% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Article: Dividend Stocks – Are They Right For You?

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply